Table 5. Study characteristics for bevacizumab-related gastrointestinal perforation.

Study	Design	No.	Platinum resistance	Number of prior regimens	Bevacizumab with cytotoxic chemo	Gastrointestinal perforation or fistula rate
Diaz et al. (2010) [24]	Retrospective cohort	160	44 (27.5)	4 (2–8)	127 (79)	6 (4)
Emile et al. (2013) [8]	Retrospective cohort	37	33 (89.2)	4 (NR)	0	0
Pietzner et al. (2011) [9]	Retrospective cohort	15	15 (100)	5.4 (1–7)	6 (40)	3 (20)
Richardson et al. (2010) [11]	Retrospective cohort	112	37 (33.0)	4 (1–10)	108 (96.4)	10 (9)
Simpkins et al. (2007) [12]	Retrospective cohort	25	25 (100)	3 (1–6)	15 (60)	0
Sfakianos et al. (2009) [25]	Retrospective cohort	68	NR	5*	45 (67)	5 (7.2)
Tanyi et al. (2011) [13]	Retrospective cohort	82	NR	3 (1–9)	NR	8 (9.76)

Values are presented as number (%) or median (range).

NR, not reported

*Mean.